BACKGROUND: Survivors of head and neck cancer (HNC) have increased risk of opioid misuse. METHODS: Using Surveillance, Epidemiology and End-Results-Medicare data, we matched adults ≥66 years diagnosed with HNC 2008-2015 with cancer-free controls. We computed odds ratios (OR) for receipt of chronic opioid therapy (COT, claims for ≥90 consecutive days) for HNC survivors compared to controls each year after matching through 2016. RESULTS: The cohort of HNC survivors declined from 5107 in the first year after diagnosis to 604 in the sixth year after diagnosis. For 5 years, rates of COT among HNC survivors exceeded that of controls. Differences between survivors and controls declined each year (ORs: year 1, 4.36; year 2, 2.60; year 3, 2.18; year 4, 1.85; and year 5, 1.35; all P-values <.05). CONCLUSIONS: Among older HNC survivors, cancer-associated opioid use in the first years after diagnosis suggests that the benefit of opioids must balance the risk of opioid misuse.
BACKGROUND: Survivors of head and neck cancer (HNC) have increased risk of opioid misuse. METHODS: Using Surveillance, Epidemiology and End-Results-Medicare data, we matched adults ≥66 years diagnosed with HNC 2008-2015 with cancer-free controls. We computed odds ratios (OR) for receipt of chronic opioid therapy (COT, claims for ≥90 consecutive days) for HNC survivors compared to controls each year after matching through 2016. RESULTS: The cohort of HNC survivors declined from 5107 in the first year after diagnosis to 604 in the sixth year after diagnosis. For 5 years, rates of COT among HNC survivors exceeded that of controls. Differences between survivors and controls declined each year (ORs: year 1, 4.36; year 2, 2.60; year 3, 2.18; year 4, 1.85; and year 5, 1.35; all P-values <.05). CONCLUSIONS: Among older HNC survivors, cancer-associated opioid use in the first years after diagnosis suggests that the benefit of opioids must balance the risk of opioid misuse.
Authors: B Mesgarpour; U Griebler; A Glechner; C Kien; M Strobelberger; M G Van Noord; A Michalek-Sauberer Journal: Eur J Pain Date: 2013-09-20 Impact factor: 3.931
Authors: Robert Dufour; Ashish V Joshi; Margaret K Pasquale; David Schaaf; Jack Mardekian; George A Andrews; Nick C Patel Journal: Pain Pract Date: 2013-12-01 Impact factor: 3.183
Authors: Dhanalakshmi Koyyalagunta; Eduardo Bruera; Daneshvari R Solanki; Kent H Nouri; Allen W Burton; Marco Perez Toro; Brian M Bruel; Laxmaiah Manchikanti Journal: Pain Physician Date: 2012-07 Impact factor: 4.965
Authors: K Robin Yabroff; William F Lawrence; Steven Clauser; William W Davis; Martin L Brown Journal: J Natl Cancer Inst Date: 2004-09-01 Impact factor: 13.506
Authors: Marieke H J van den Beuken-van Everdingen; Laura M J Hochstenbach; Elbert A J Joosten; Vivianne C G Tjan-Heijnen; Daisy J A Janssen Journal: J Pain Symptom Manage Date: 2016-04-23 Impact factor: 3.612
Authors: David J Adelstein; Yi Li; George L Adams; Henry Wagner; Julie A Kish; John F Ensley; David E Schuller; Arlene A Forastiere Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Lucian Zhao; Dominic H Moon; Vladimir Avkshtol; Caitlin H Siropaides; Stephanie Terauchi; Andrew T Day; Baran D Sumer; Randall Hughes; David J Sher Journal: Support Care Cancer Date: 2022-06-06 Impact factor: 3.359